J. Corvalan

发表

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

Larry L. Green, Atsushi Fukushima, K. Zsebo, 1997, Nature Genetics.

Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.

M. Jeffers, H. Lichenstein, Frank Wu, 2002, Cancer research.

Use of monoclonal antibodies for the histopathological diagnosis of human malignancy

H. Stein, J. Taylor‐Papadimitriou, D. Mason, 1982, Journal of clinical pathology.

New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.

S. Briggs, J. J. Starling, T. Bumol, 1989, Journal of medicinal chemistry.

In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen.

S. Briggs, J. J. Starling, J. Corvalan, 1992, Bioconjugate chemistry.

Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci

L. Pirofski, N. Russell, C. Davis, 2000, Infection and Immunity.

Therapy of streptozotocin induced diabetes with a bifunctional antibody that delivers vinca alkaloids to IL-2 receptor positive cells.

E. Petrella, C. Knott, J. Corvalan, 1995, Autoimmunity.

Fully human anti‐interleukin‐8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states

C. Davis, Xiao-Dong Yang, J. Corvalan, 1999, Journal of leukocyte biology.

Antitumor properties of vindesine-monoclonal antibody conjugates

R. W. Baldwin, J. Brown, R. G. Simmonds, 2004, Cancer Immunology, Immunotherapy.

Transgenic Mice as a Source of Fully Human Antibodies for the Treatment of Cancer

C. Davis, J. Corvalan, M. Gallo, 2004, Cancer and Metastasis Reviews.

Production of an H–2-related suppressor factor by a hybrid T-cell line

M. Taussig, R. Binns, J. Corvalan, 1979, Nature.

Immunoglobulin Loci Transgenic Mice with Human Antipneumococcal Antibodies by Production of Protective Human

L. Pirofski, N. Russell, C. Davis, 2000 .

Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates.

J. J. Starling, J. Corvalan, P. Marder, 1988, Cancer research.

Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.

M. Ritter, A. Epenetos, J. Corvalan, 1991, British Journal of Cancer.

Reduction of toxicity of a vinca alkaloid by an anti-vinca alkaloid antibody.

J. Corvalan, D. Johnson, M. Gutowski, 1995, Cancer investigation.

Tumour therapy with vinca alkaloids targeted by a hybrid‐hybrid monoclonal antibody recognising both CEA and vinca alkaloids

J. Corvalan, W. Smith, V. Gore, 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Anticorps anti-OPGL

W. J. Boyle, J. Corvalan, G. C. Davis, 2002 .

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

C. Davis, X. Jia, J. Corvalan, 2001, Critical reviews in oncology/hematology.

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

C. Davis, X. Jia, J. Corvalan, 1999, Cancer research.

Immune response genes controlling responsiveness to major transplantation antigens. Specific major histocompatibility complex- linked defect for antibody responses to class I alloantigens

J. Howard, G. Butcher, J. Corvalan, 1982, The Journal of experimental medicine.

CHARACTERIZATION OF AN ANTIGEN‐SPECIFIC FACTOR FROM A HYBRID T‐CELL LINE *

M. Taussig, J. Corvalan, A. Holliman, 1979, Annals of the New York Academy of Sciences.

T-cell hybrids as a source of antigen-specific factors.

M. Taussig, J. Corvalan, A. Holliman, 1980, Transplantation proceedings.

Zyme, a Novel and Potentially Amyloidogenic Enzyme cDNA Isolated from Alzheimer’s Disease Brain*

James R. Miller, D. Stephenson, E. Dixon, 1997, The Journal of Biological Chemistry.

Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci1

Yuxian He, A. Pinter, M. Burkhart, 2002, The Journal of Immunology.

Demonstration of MHC-specific haemolytic plaque-forming cells

J. Howard, J. Corvalan, 1979, Nature.

Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis.

J. Corvalan, N. Hall, M. McKeown, 1984, Clinical and experimental immunology.

Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies.

J. Corvalan, R. Beattie, W. Smith, 1992, Hybridoma.

Classification of Anti-CEA Monoclonal Antibodies

Clive S. Woodhouse, J. Corvalan, D. R. Brandon, 1984 .

Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine

J. Corvalan, D. R. Brandon, W. Smith, 2005, Cancer Immunology, Immunotherapy.

Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody

J. Corvalan, D. R. Brandon, W. Smith, 2004, Cancer Immunology, Immunotherapy.

Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids

J. Corvalan, J. R. F. Corvalan, W. Smith, 2004, Cancer Immunology, Immunotherapy.

Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids

J. Corvalan, J. R. F. Corvalan, W. Smith, 2004, Cancer Immunology, Immunotherapy.

Primary in vitro antibody formation in the rat: partial characterization and properties of an inhibitor cell present in normal spleen

J. Howard, J. Corvalan, J. R. F. Corvalán, 1978, European journal of immunology.